Overview

PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the potential effect of renal impairment on the systemic pharmacokinetics of acute Intranasal RX0041-002. The secondary objective is to evaluate the safety and tolerability of acute Intranasal RX0041-002 in subjects with normal renal function and severe renal impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmaceutical Project Solutions, Inc.
Collaborator:
Cognitive Research Corporation